Research press release


Nature Microbiology

Medical research: SARS-CoV-2 immune response related to disease severity

重症急性呼吸器症候群コロナウイルス2(SARS-CoV-2)に対する免疫応答は、感染後3か月で減衰し、疾患の重症度に関連していることを示した報告がNature Microbiology に掲載される。今回の研究は、ウイルスに対する体の応答についての手掛かりであり、ワクチンの設計や疾患管理に大きな意味を持つだろう。

SARS-CoV-2の感染者では、このウイルスに対する免疫応答が起こるが、その持続期間は不明確で、その患者がどの程度の期間、感染から守られるかは分かっていない。今回、Katie Dooresたちは、ロンドンにあるガイズ&聖トーマス病院の患者59人と医療従事者37人を対象に、最初に症状が出てから3か月間の抗体応答を調べた。



The immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wanes in the three months following infection and is dependent on the severity of the disease, suggests a paper in Nature Microbiology. The study, which provides insights into the body’s response to the virus, has notable implications for vaccine design and disease management.

Although people infected with SARS-CoV-2 generate an immune response to the virus, the duration of the response is uncertain and it has been unclear how long individuals will be protected for. Katie Doores and colleagues studied the antibody response of 59 patients and 37 healthcare workers at Guy’s and St Thomas’ NHS Foundation Trust in London for three months following the onset of their symptoms.

Typical of an acute viral infection, the antibody response peaked at around one month after the onset of symptoms, before starting to decline. People with severe disease generated the strongest antibody response, and although this response diminished, neutralizing antibodies were still detectable more than 60 days after symptoms began. People with milder disease also generated an immune response, but it was smaller and declined towards baseline levels. Some healthcare workers, for example, had no detectable immune response within the same follow-up period.

The study suggests that people who experience more severe COVID-19 disease may be protected for longer periods than people who experience milder symptoms, and that the kinetics of the response are similar to other endemic seasonal coronaviruses. The authors note that vaccines will need to generate a robust and long-lasting immune response akin to that generated in severely ill patients, and that boosters may be required to provide long-lasting protection.

doi: 10.1038/s41564-020-00813-8


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。